AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy right now. In a report released on September 11, Vamil Divan from Guggenheim reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV), setting a price target of $227.00. AbbVie (ABBV)'s Dividend Track Record: How It Became a Leader in Consistent Dividends In its fiscal Q2 2025 results, AbbVie Inc. (NYSE:ABBV) reported a diluted EPS of $0.52 on a GAAP basis, reflecting a decrease of 32.5%. Adjusted diluted EPS for the quarter reached $2.97, up 12.1%. ...

POET Technologies Inc. (NASDAQ:POET) is one of the best AI stocks to buy according to analysts. On August 29, POET Technologies Inc. announced a partnership with NTT Innovative Devices Corporation, which is a subsidiary of Japan’s leading telecom company, to develop advanced optical engines. The collaboration supports next-gen mobile networks that will enable widespread use of AI applications on mobile devices. The development will focus on a 100G Bidirectional Optical Engine for mobile front-haul network ...

Nebius Group (NASDAQ:NBIS) is one of the best AI stocks to buy according to analysts. On September 9, BWS Financial raised the firm’s price target on Nebius to $130 from $90, while keeping a Buy rating on the shares after the company announced its first hyperscaler contract worth ~$19.4 billion with Microsoft Corp.  (NASDAQ:MSFT) over 5 years. With Nebius having a major contract in hand, the company is expected to accelerate GPU installations and bring New Jersey online as fast as possible. Earlier in Aug ...

Eli Lilly and Company (NYSE:LLY) is one of the best drug stocks to buy right now. Citi analyst Geoff Meacham maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) on September 10, retaining the price target of $1,190.00. Was Jim Cramer Right About Eli Lilly and Company (LLY)? The analyst supported the optimistic outlook with the promising outlook for the company’s obesity treatment, tirzepatide, stating that the treatment attained the highest cost-effectiveness rating in the recent draft report by ...

we discuss ideas like this as they happen in more detail. All active investors are welcome to join on a free trial and ask any question in our chat room full of sophisticated traders and investors.As common stocks still appear overvalued, we are turning our attention to high-quality, publicly traded preferred stocks. We are increasing our exposure to fixed-income instruments as we believe they offer the potential for unrealized returns. In pursuit of an optimalDenislav leads the investing group Trade With B ...

Codexis (NASDAQ: CDXS ) has enzymatic solutions that help improve the efficiency of pharmaceutical research and production. They’re currently evolving from selling enzyme parts to also becoming an integrated siRNA supplier with their ECO synthesis technology. In theory, thisMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science from Ohio University, Athens, OH, USA, a ...

Apple Inc. (NASDAQ: AAPL) may emerge as one of the largest beneficiaries of on-device artificial intelligence (AI) in the months ahead, according to Bernstein analyst Mark Newman. ...

If you have found my strategies interesting, useful, or profitable, consider supporting my continued research by joining the Cyclical Investor's Club . It's only $499/year.I have a unique and unusual strategy when it comes to investing in the stocks of deeply cyclical businesses like Micron Technology, Inc. (NASDAQ: MU ). Because of the uniqueness of the strategy, I like toCory leads the investing group The Cyclical Investor's Club where he shares his unique mix of investing strategies that focus on All-Wea ...

All right, welcome back to Power Lunch. Let's talk about tomorrow's big Federal Reserve meeting and maybe one group of stocks that could benefit. It is the subject of today's market navigator.That is Dom Chu. What is on the market navigator. All right, so as we talk about tomorrow, the Fed is all but certain to cut interest rates by at least one quarter of 1%.But our next guest says that bank stocks are going to stand to benefit from a rate cut and says that in fact the sector has been overlooked and could ...

Hemostemix to Present Its Clinical Data of the Treatment of Severe AnginaSeptember 16, 2025 2:52 PM EDT | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, ...